_id
69104fa5ccc777a4e85d53ad
Ticker
CLGN
Name
Collplant Biotechnologies Ltd
Exchange
NASDAQ
Address
Weizmann Science Park, Rehovot, Israel, 7670104
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://collplant.com
Description
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Last Close
1.9
Volume
13445
Current Price
1.81
Change
-4.73684210526315
Last Updated
2025-11-29T11:32:23.077Z
Image
data:image/webp;base64,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
Ipo Date
2018-01-30T00:00:00.000Z
Market Cap
27952174
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
5
Target Price
11.56
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
179000
Cost Of Revenue
415000
Gross Profit
-236000
Operating Expenses
2942000
Operating Income
-3178000
Interest Expense
169000
Pretax Income
-3347000
Net Income
-3347000
Eps
-0.28266601941468794
Dividends Per Share
-
Shares Outstanding
12776385
Income Tax Expense
-
EBITDA
-2949000
Operating Margin
-1775.418994413408
Total Other Income Expense Net
-169000
Cash
11707000
Short Term Investments
-
Receivables
0
Inventories
553000
Total Current Assets
12624000
Property Plant Equipment
4581000
Total Assets
17437000
Payables
571000
Short Term Debt
837000
Long Term Debt
-
Total Liabilities
4932000
Equity
12505000
Depreciation
229000
Change In Working Capital
406298
Cash From Operations
-2457391
Capital Expenditures
3058
Cash From Investing
-3053
Cash From Financing
3116956
Net Change In Cash
727000
PE
-
PB
1.7138664926029588
ROE
-26.765293882447022
ROA
-19.194815621953317
FCF
-2460449
Fcf Percent
-13.745525139664805
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
4
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
3
Quality Investing Score
2.5
Value Investing Score
4
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
179000
Quarters > 0 > income Statement > cost Of Revenue
415000
Quarters > 0 > income Statement > gross Profit
-236000
Quarters > 0 > income Statement > operating Expenses
2942000
Quarters > 0 > income Statement > operating Income
-3178000
Quarters > 0 > income Statement > interest Expense
169000
Quarters > 0 > income Statement > pretax Income
-3347000
Quarters > 0 > income Statement > net Income
-3347000
Quarters > 0 > income Statement > eps
-0.28266601941468794
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
11840829
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-2949000
Quarters > 0 > income Statement > operating Margin
-1775.418994413408
Quarters > 0 > income Statement > total Other Income Expense Net
-169000
Quarters > 0 > balance Sheet > cash
11707000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
0
Quarters > 0 > balance Sheet > inventories
553000
Quarters > 0 > balance Sheet > total Current Assets
12624000
Quarters > 0 > balance Sheet > property Plant Equipment
4581000
Quarters > 0 > balance Sheet > total Assets
17437000
Quarters > 0 > balance Sheet > payables
571000
Quarters > 0 > balance Sheet > short Term Debt
837000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
4932000
Quarters > 0 > balance Sheet > equity
12505000
Quarters > 0 > cash Flow > net Income
-3347000
Quarters > 0 > cash Flow > depreciation
229000
Quarters > 0 > cash Flow > change In Working Capital
406298
Quarters > 0 > cash Flow > cash From Operations
-2457391
Quarters > 0 > cash Flow > capital Expenditures
3058
Quarters > 0 > cash Flow > cash From Investing
-3053
Quarters > 0 > cash Flow > cash From Financing
3116956
Quarters > 0 > cash Flow > net Change In Cash
727000
Quarters > 0 > ratios > PE
-0.28266601941468794
Quarters > 0 > ratios > PB
1.7138664926029588
Quarters > 0 > ratios > ROE
-26.765293882447022
Quarters > 0 > ratios > ROA
-19.194815621953317
Quarters > 0 > ratios > FCF
-2460449
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-13.745525139664805
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
2055000
Quarters > 1 > income Statement > cost Of Revenue
188000
Quarters > 1 > income Statement > gross Profit
1867000
Quarters > 1 > income Statement > operating Expenses
3515000
Quarters > 1 > income Statement > operating Income
-1648000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-1452000
Quarters > 1 > income Statement > net Income
-1452000
Quarters > 1 > income Statement > eps
-0.1267622749882317
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
11454512
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-1404000
Quarters > 1 > income Statement > operating Margin
-80.19464720194647
Quarters > 1 > income Statement > total Other Income Expense Net
196000
Quarters > 1 > balance Sheet > cash
10735000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
440000
Quarters > 1 > balance Sheet > inventories
673000
Quarters > 1 > balance Sheet > total Current Assets
12093000
Quarters > 1 > balance Sheet > property Plant Equipment
4882000
Quarters > 1 > balance Sheet > total Assets
17208000
Quarters > 1 > balance Sheet > payables
770000
Quarters > 1 > balance Sheet > short Term Debt
732000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
4811000
Quarters > 1 > balance Sheet > equity
12397000
Quarters > 1 > cash Flow > net Income
-1452000
Quarters > 1 > cash Flow > depreciation
244000
Quarters > 1 > cash Flow > change In Working Capital
-344000
Quarters > 1 > cash Flow > cash From Operations
-1167000
Quarters > 1 > cash Flow > capital Expenditures
9000
Quarters > 1 > cash Flow > cash From Investing
-8000
Quarters > 1 > cash Flow > cash From Financing
0
Quarters > 1 > cash Flow > net Change In Cash
-1174000
Quarters > 1 > ratios > PE
-0.1267622749882317
Quarters > 1 > ratios > PB
1.6723938630313786
Quarters > 1 > ratios > ROE
-11.712511091393079
Quarters > 1 > ratios > ROA
-8.437935843793584
Quarters > 1 > ratios > FCF
-1176000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.5722627737226277
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
164000
Quarters > 2 > income Statement > cost Of Revenue
272000
Quarters > 2 > income Statement > gross Profit
-108000
Quarters > 2 > income Statement > operating Expenses
3866000
Quarters > 2 > income Statement > operating Income
-3974000
Quarters > 2 > income Statement > interest Expense
17000
Quarters > 2 > income Statement > pretax Income
-3878000
Quarters > 2 > income Statement > net Income
-3878000
Quarters > 2 > income Statement > eps
-0.3385565443556216
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
11454512
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-3732000
Quarters > 2 > income Statement > operating Margin
-2423.170731707317
Quarters > 2 > income Statement > total Other Income Expense Net
96000
Quarters > 2 > balance Sheet > cash
11909000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
583000
Quarters > 2 > balance Sheet > inventories
440000
Quarters > 2 > balance Sheet > total Current Assets
13180000
Quarters > 2 > balance Sheet > property Plant Equipment
5281000
Quarters > 2 > balance Sheet > total Assets
18710000
Quarters > 2 > balance Sheet > payables
870000
Quarters > 2 > balance Sheet > short Term Debt
806000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
5245000
Quarters > 2 > balance Sheet > equity
13465000
Quarters > 2 > cash Flow > net Income
-3878000
Quarters > 2 > cash Flow > depreciation
242000
Quarters > 2 > cash Flow > change In Working Capital
-182698
Quarters > 2 > cash Flow > cash From Operations
-3464000
Quarters > 2 > cash Flow > capital Expenditures
59000
Quarters > 2 > cash Flow > cash From Investing
-58000
Quarters > 2 > cash Flow > cash From Financing
0
Quarters > 2 > cash Flow > net Change In Cash
-3462000
Quarters > 2 > ratios > PE
-0.3385565443556216
Quarters > 2 > ratios > PB
1.539745021908652
Quarters > 2 > ratios > ROE
-28.800594132937245
Quarters > 2 > ratios > ROA
-20.726884019241048
Quarters > 2 > ratios > FCF
-3523000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-21.48170731707317
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
4000
Quarters > 3 > income Statement > cost Of Revenue
272000
Quarters > 3 > income Statement > gross Profit
-268000
Quarters > 3 > income Statement > operating Expenses
4274000
Quarters > 3 > income Statement > operating Income
-4542000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-4326000
Quarters > 3 > income Statement > net Income
-4326000
Quarters > 3 > income Statement > eps
-0.37766776969634325
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
11454512
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-4287000
Quarters > 3 > income Statement > operating Margin
-113550
Quarters > 3 > income Statement > total Other Income Expense Net
216000
Quarters > 3 > balance Sheet > cash
15371000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
431000
Quarters > 3 > balance Sheet > inventories
454000
Quarters > 3 > balance Sheet > total Current Assets
16497000
Quarters > 3 > balance Sheet > property Plant Equipment
5685000
Quarters > 3 > balance Sheet > total Assets
22442000
Quarters > 3 > balance Sheet > payables
1009000
Quarters > 3 > balance Sheet > short Term Debt
798000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
5524000
Quarters > 3 > balance Sheet > equity
16918000
Quarters > 3 > cash Flow > net Income
-4326000
Quarters > 3 > cash Flow > depreciation
255000
Quarters > 3 > cash Flow > change In Working Capital
154000
Quarters > 3 > cash Flow > cash From Operations
-3448000
Quarters > 3 > cash Flow > capital Expenditures
140000
Quarters > 3 > cash Flow > cash From Investing
-140000
Quarters > 3 > cash Flow > cash From Financing
0
Quarters > 3 > cash Flow > net Change In Cash
-3549000
Quarters > 3 > ratios > PE
-0.37766776969634325
Quarters > 3 > ratios > PB
1.2254797682941245
Quarters > 3 > ratios > ROE
-25.570398392244947
Quarters > 3 > ratios > ROA
-19.276356830941985
Quarters > 3 > ratios > FCF
-3588000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-897
Quarters > 3 > health Score
35
Valuation > metrics > PE
-0.28266601941468794
Valuation > metrics > PB
1.7138664926029588
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-26.765293882447022
Profitability > metrics > ROA
-26.51299112801014
Profitability > metrics > Net Margin
-18.69832402234637
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.39440223910435823
Risk > metrics > Interest Coverage
-18.80473372781065
Risk > final Score
-15
Risk > verdict
High
Liquidity > metrics > Current Ratio
8.965909090909092
Liquidity > metrics > Quick Ratio
8.573153409090908
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-77
Prev Risks > 1
-875
Prev Risks > 2
-406
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:20:30.440Z
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AD. Boral Capital Maintains CollPlant Biotechnologies (CLGN) Buy Recommendation Nasdaq
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
STRONG BUY
Target Price:
$11.56
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.07% of the total shares of Collplant Biotechnologies Ltd
1.
Fidelity Nasdaq Composite Index(0.0466%)
since
2025/07/31
2.
Parallel Advisors, LLC(0.0256%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.